Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

NEXT STORY
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
PREV STORY
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CDPHP Offers Housing, Hope for Homeless Members

Albany, NY-based health insurer providers affordable housing for at-risk membersAlbany, NY, Dec. 21, 2018 ...

author_avatar
NASDAQ Market News

Sunshine Heart Announces OPTIONS HF Clinical Experience

EDEN PRAIRIE, Minn., May 24, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced ...

author_avatar
NASDAQ Market News

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results

NEWTOWN, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase ...

author_avatar
NASDAQ Market News